A Phase 3, Open-label Clinical Study to Evaluate the Immunogenicity and Safety of 9vHPV Vaccine, in Japanese Boys and Girls, 9 to 15 Years of Age
Latest Information Update: 11 Oct 2024
At a glance
- Drugs V 503 (Primary)
- Indications Human polyomavirus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 19 Apr 2024 Status changed from active, no longer recruiting to completed.
- 17 Nov 2021 Planned End Date changed from 26 Aug 2024 to 26 Apr 2024.
- 17 Nov 2021 Planned primary completion date changed from 26 Aug 2024 to 26 Apr 2024.